EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
European Union seeks input from rival pharmaceutical firms on Novo Holding $16.5 billion acquisition of Catalent.
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
Zacks.com on MSN12d
Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin UpCTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours ...
The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...
Reuters on MSN14d
Catalent Misses Q1 Revenue Estimates Ahead of $16.5 Billion Deal Close With Novo HoldingsCatalent's revenue for fiscal first quarter ended Sept. 30 was $1.02 billion, marginally below analysts' estimates of $1.06 ...
The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...
Catalent (NYSE:CTLT – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report ...
European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 billion purchase of Catalent (NYSE:CTLT). The questionnaire from the ...
Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have been given a consensus rating of “Hold” by the eight ratings firms that are presently covering the stock, MarketBeat reports. Eight ...
Jefferies analyst David Windley maintained a Hold rating on Catalent (CTLT – Research Report) today and set a price target of $63.50.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback